# Evaluation of Eflornithine Plus Temozolomide in Patients With Newly Diagnosed Glioblastoma or Astrocytoma

> **NCT05879367** · PHASE1 · RECRUITING · sponsor: **Orbus Therapeutics, Inc.** · enrollment: 66 (estimated)

## Conditions studied

- Glioblastoma, IDH-wildtype
- Glioblastoma
- Glioblastoma Multiforme
- Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype
- GBM
- Astrocytoma
- Astrocytoma, IDH-Mutant

## Interventions

- **DRUG:** Eflornithine (Dose Level 1)
- **DRUG:** Eflornithine (Dose Level 2)
- **DRUG:** Eflornithine (Dose Level -1)
- **DRUG:** Temozolomide

## Key facts

- **NCT ID:** NCT05879367
- **Lead sponsor:** Orbus Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-07-24
- **Primary completion:** 2026-06-30
- **Final completion:** 2026-06-30
- **Target enrollment:** 66 (ESTIMATED)
- **Last updated:** 2025-06-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05879367

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05879367, "Evaluation of Eflornithine Plus Temozolomide in Patients With Newly Diagnosed Glioblastoma or Astrocytoma". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT05879367. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*